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In a large population-based series of invasive breast cancer patients, we investigated socioeconomic background (SEB) in relation to
(a) stage at diagnosis; (b) treatment pattern; and (c) 5-year survival. Women diagnosed during 1998–2000 and resident in the
Northern and Yorkshire regions of England were identified from the cancer registry database (N¼12768). Logistic regression and
Cox proportional hazards analyses were used to estimate associations between SEB (defined using the Townsend Index for area of
residence) and tumour stage, treatment pattern, and survival. Living in a more deprived area was associated with increased likelihood
of being diagnosed with stage III or IV disease (age-adjusted odds ratio (OR) 1.13; 95% confidence interval (CI) 1.08–1.18 per
quartile increase in Townsend score), and, after adjustment for age and stage, reduced odds of having surgery (OR 0.85; 95% CI
0.80–0.91), and receiving radiotherapy (OR 0.91; 95% CI 0.88–0.94). Amongst patients receiving surgery, those living in more
deprived areas had decreased odds of having breast conserving surgery (age plus stage-adjusted OR 0.92; 95% CI 0.89–0.95). Living
in a more deprived area was also associated with increased mortality (age- plus stage-adjusted hazard ratio 1.08; 95% CI 1.05–1.11).
These effects may operate through several pathways, such as later presentation leading to advanced disease.
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Breast cancer is the commonest female cancer in the UK,
accounting for about 30% of all cancers in women (Cancer
Research UK, 2006). Owing to a combination of its natural history,
methods for early diagnosis and effective treatment, survival
from breast cancer is better than that of many other cancers
(Department of Health, 2000). Differences in survival according to
socioeconomic background (SEB) have, however, been reported
from the UK, with women from more deprived areas showing
lower survival rates than those from more affluent areas of
residence, with differences of 6% at 5 years (Coleman et al, 2004),
and 10% at 10 years (Thomson et al, 2001).
Socioeconomic background has been associated with differences
in tumour biology, such as type, grade, and oestrogen receptor
(ER) status (Thomson et al, 2001; Taylor and Cheng, 2003), stage at
diagnosis (Macleod et al, 2000a; Adams et al, 2004), variation in
diagnostic investigations and treatments (Twelves et al, 1998) and
comorbidity (Macleod et al, 2000b). However, certain findings
have been inconsistent, such as differences in stage by level of area
deprivation, which have been observed in some (Macleod et al,
2000a; Adams et al, 2004) but not in other studies (Carnon et al,
1994; Brewster et al, 2001; Thomson et al, 2001; Taylor and Cheng,
2003). Attempts to explain socioeconomic differences in survival
on the basis of stage and treatment have also produced conflicting
results, which may reflect differing health service provisions and
socioeconomic structures in the relevant countries (Thomson et al,
2001).
We have investigated the relationship between SEB and (a) stage
at diagnosis, (b) treatment patterns and (c) 5-year survival, in a
large population-based sample of invasive breast cancer patients
diagnosed in 1998 to 2000.
MATERIALS AND METHODS
Women with invasive breast cancer (ICD10; (World Health
Organisation, 1992; code C50) diagnosed in the years 1998–2000
and resident in the Northern and Yorkshire regions were identified
from the Northern and Yorkshire Cancer Registry and Information
Service database. Patient age and tumour stage at diagnosis (using
the TNM system; Singletary et al, 2002), treatment (type of surgery
and whether or not radiotherapy (RT), chemotherapy (CT), or
hormone therapy (HT) were given), the time taken to receive a
hospital appointment after GP referral (appointment delay), and
the time taken to receive treatment after diagnosis (treatment
delay) were extracted. SEB was defined at the 1991 enumeration
district level of residence using the Townsend index (Townsend
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yand Phillimore, 1988) and matched to the patient using their
postcode. An area deprivation score could not be obtained in
40 cases.
All factors were examined in relation to quartiles of area depri-
vation (Townsend score) (Table 1). Logistic regression analyses
were used to examine any associations between SEB and stage or
treatment (type of surgery, use of adjuvant treatments, appoint-
ment delay and treatment delay), whereas Cox proportional
hazards analyses (Cox, 1972) were used to evaluate any association
between SEB and 5-year survival. Models were adjusted for age or
age plus stage. Proportionality assumptions were verified for all
survival models.
The Townsend score was scaled and included as a continuous
variable such that the resulting odds ratios (ORs) or hazard ratios
(HRs) represent a change in the outcome per quartile increase
in the Townsend score. As details of some factors were not
available for all patients (Table 1), analyses were conducted after
the exclusion of ‘unknowns’ for the factor under investigation.
RESULTS
A total of 12768 patients were included in the analyses. A higher
proportion of patients living in the most deprived quartile (45.3%;
95% confidence interval (CI) 43.6–47.0) were older than 65 years
at diagnosis compared to those living in the most affluent quartile
(35.9%; 95% CI 34.2–37.6) (Table 1). Patients living in the most
affluent quartile were diagnosed more frequently with stage I
Table 1 Distribution of patient, tumour, and treatment factors in the study population, by deprivation category
All patients
Townsend quartile
Variable N (%) I (affluent) II III IV (deprived)
Age
o50 2698 (21.1) 696 (21.8) 706 (22.2) 657 (20.6) 639 (20.0)
50–64 4812 (37.7) 1354 (42.3) 1254 (39.3) 1097 (34.4) 1107 (34.7)
65+ 5258 (41.2) 1148 (35.9) 1227 (38.5) 1438 (45.1) 1445 (45.3)
Stage
I 4539 (39.2) 1235 (42.0) 1202 (40.8) 1063 (37.3) 1039 (36.3)
II 5576 (48.1) 1380 (47.0) 1414 (48.0) 1416 (49.7) 1366 (47.8)
III 900 (7.8) 210 (7.1) 220 (7.5) 217 (7.6) 253 (8.8)
IV 578 (5.0) 114 (3.9) 110 (3.7) 153 (5.4) 201 (7.0)
Surgery
BCS alone 4605 (36.2) 1288 (40.4) 1250 (39.4) 1058 (33.3) 1009 (31.7)
Mastectomy alone 4721 (37.1) 1146 (36.0) 1141 (35.9) 1201 (37.8) 1233 (38.8)
BCS and mastectomy
a 1178 (9.3) 332 (10.4) 319 (10.1) 293 (9.2) 234 (7.4)
No surgery 2217 (17.4) 421 (13.2) 464 (14.6) 627 (19.7) 705 (22.2)
Radiotherapy
Yes 6734 (53.6) 1831 (58.3) 1755 (56.1) 1602 (50.9) 1546 (49.0)
No 5837 (46.4) 1309 (41.7) 1371 (43.9) 1548 (49.1) 1609 (51.0)
Surgery and RT
b
BCS alone 3951 (86.6) 1123 (88.2) 1068 (86.5) 894 (85.1) 866 (86.3)
Mastectomy alone 2079 (44.8) 524 (46.8) 517 (46.3) 525 (44.4) 513 (42.2)
BCS and mastectomy
a 396 (34.3) 120 (37.5) 109 (34.9) 100 (35.4) 67 (28.9)
No surgery 304 (13.7) 62 (14.8) 61 (13.2) 81 (12.9) 100 (14.2)
Hormone therapy
Yes 10285 (81.2) 2540 (80.4) 2535 (80.4) 2605 (82.1) 2605 (82.1)
No 2376 (18.8) 621 (19.6) 618 (19.6) 568 (17.9) 569 (17.9)
Chemotherapy
Yes 3536 (28.1) 917 (29.2) 898 (28.7) 888 (28.2) 833 (26.4)
No 9036 (71.9) 2223 (70.8) 2231 (71.3) 2262 (71.8) 2320 (73.6)
Appointment delay
0–14 days 5290 (60.7) 1302 (62.7) 1258 (60.1) 1397 (61.4) 1333 (58.6)
15–28 days 2051 (23.5) 483 (23.2) 489 (23.4) 516 (22.7) 563 (24.8)
29–60 days 1028 (11.8) 219 (10.5) 250 (12.0) 273 (12.0) 286 (12.6)
61–180 days 351 (4.0) 74 (3.6) 95 (4.5) 90 (4.0) 92 (4.0)
Treatment delay
0–14 days 7461 (60.2) 1932 (61.9) 1845 (59.6) 1855 (60.1) 1829 (59.3)
15–28 days 3442 (27.8) 842 (27.0) 881 (28.5) 844 (27.3) 875 (28.4)
29–60 days 1342 (10.8) 317 (10.2) 335 (10.8) 350 (11.3) 340 (11.0)
61–180 days 141 (1.1) 28 (0.9) 33 (1.1) 38 (1.2) 42 (1.4)
BCS¼breast conserving surgery; RT¼radiotherapy. Number of cases excluded from each variable owing to unknown status is as follows: stage; 1175 cases, surgery allocation;
47 cases, radiotherapy; 197 cases, hormone therapy; 107 cases, chemotherapy; 196 cases, appointment delay; 4048 cases, treatment delay; 382 cases.
aBCS before mastectomy.
bProportion of patients that received RT, by type of surgery.
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ydisease (42.0%; 95% CI 40.2–43.8) than those in the most
deprived quartile (36.3%; 95% CI 34.6–38.1), whereas a higher
proportion of those with metastatic disease (stage IV) lived in the
most deprived quartile (7.0%; 95% CI 6.1–8.0) compared to the
most affluent quartile (3.9%; 95% CI 3.2–4.6). A higher proportion
of patients living in the most affluent quartile had breast-
conserving surgery (BCS) compared to those in the most deprived
quartile, either alone (40.4%; 95% CI 38.7–42.1 vs 31.7%; 95% CI
30.1–33.3) or before mastectomy (10.4%; 95% CI 9.4–11.5 vs 7.4%;
95% CI 6.4–8.3), a greater proportion of those living in the
most deprived quartile received no surgery (22.2%; 95% CI 20.7–
23.6 vs 13.2% ; 95% CI 12.0–14.4). A higher proportion of the
patients resident in the most affluent quartile received RT (58.3%;
95% CI 56.6–60.0) compared to those in the most deprived
quartile (49.0%; 95% CI 47.3–50.7). There was no statistically
significant difference in the proportion of patients having BCS
with subsequent RT (86.3%; 95% CI 84.2–88.5 and 88.2%; 95% CI
86.4–90.0 in the most deprived and most affluent quartiles
respectively) nor in the proportions receiving HT (82.1%;
95% CI 80.7–83.4 vs 80.4%; 95% CI 79.0–81.7) and CT (26.4%;
95% CI 24.9–28.0 vs 29.2%; 95% CI 27.6–30.8). Women living
in the most affluent quartile were more frequently seen within
14 days of referral (62.7%; 95% CI 60.6–64.7) compared to
those in the most deprived quartile (58.6%; 95% CI 56.6–60.6) but
this difference was less for beginning treatment within 14 days
of being diagnosed (61.9%; 95% CI 60.2–63.6 vs 59.3%; 95% CI
57.5–61.0).
The logistic regression analyses show that, after adjustment for
age, living in a more deprived area was associated with a
significantly increased odds of being diagnosed with stage III or
IV disease (OR 1.13; 95% CI 1.08–1.18 per quartile increase in
Townsend score) (Table 2). After adjustment for age and stage,
living in a more deprived area was significantly associated with
decreased odds of receiving surgery (OR 0.85; 95% CI 0.80–0.91)
and RT (OR 0.91; 95% CI 0.88–0.94). Amongst patients receiving
surgery, living in a more deprived area was associated with
significantly decreased odds of having BCS (OR 0.92; 95% CI 0.89–
0.95 per quartile increase), and significantly increased odds of
having a mastectomy (OR 1.08; 95% CI 1.05–1.12). Area Townsend
score was not significantly associated with the odds of CT (OR
0.97; 95% CI 0.93–1.01), although the association was of border-
line significance for HT (OR 1.04; 95% CI 1.00–1.08). Living in a
more deprived area was also associated with an appointment delay
of more than 14 days (OR 1.07; 95% CI 1.03–1.11) and a treatment
delay of more than 14 days (OR 1.05; 95% CI 1.02–1.08). The age
plus stage-adjusted results differed little from the age-adjusted
results, and only in the case of treatment delay did the estimate
become statistically significant after additional adjustment for
stage.
Following age adjustment, living in a more deprived area was
associated with an increased risk of death (HR 1.11; 95% CI 1.08–
1.13 per quartile increase in Townsend score), which was reduced
after adjusting for stage (HR 1.08; 95% CI 1.05–1.11) (Table 3).
When these analyses were repeated separately for patients under-
going BCS, having a mastectomy and having no surgery, there was
a stronger association between Townsend score and survival for
the BCS group (age plus stage-adjusted HR 1.13; 95% CI 1.07–1.19
per quartile increase) than for the mastectomy group (HR 1.04;
95% CI 1.00–1.08) and the no surgery group (HR 1.03; 95% CI
0.98–1.08); these results differed little from the age-adjusted
results.
DISCUSSION
Our results show that patients living in more deprived areas were
more likely to be diagnosed with more advanced (stage III or IV)
disease. This may be related to later presentation and lower rates
of mammography screening in lower SEB areas. This finding
contrasts with those of several other studies (Brewster et al, 2001;
Thomson et al, 2001; Taylor and Cheng, 2003). However, this study
was based on a much larger number of patients and staging data
were available in over 90% of cases.
Women living in more deprived areas were less likely to
have surgical treatment than those in affluent areas, and when
they had surgery they were more likely to have a mastectomy.
Adjustment for stage of disease at diagnosis made little
difference to these results. Decisions about whether or not patients
receive surgery and the type of surgery performed are the outcome
of, in many cases, a complex interaction between stage and
evaluation of the choices offered to patients by their clinical
management team, the manner in which these choices are
presented, and perceptions of the risks and benefits involved.
The extent to which the latter factors may vary by SEB is poorly
understood.
RT was the only adjuvant treatment found to be significantly
related to SEB, with women in more deprived areas being less
likely to receive this. RT for breast cancer can be intensive,
involving visits to a RT centre for several days each week over
several weeks, and this may have more impact on the treatment
decisions of women in socially deprived areas. Other UK studies
have found no difference in the uptake of RT by SEB (Macleod
et al, 2000b; Thomson et al, 2001). When analysis was restricted
to BCS patients, there was no significant difference in RT by SEB.
BCS followed by RT is considered an optimal treatment and it is
Table 2 Association between socioeconomic status and patient and
treatment factors (Odds Ratios per quartile increase in Townsend score)
Unadjusted OR
(95% CI)
Age-adjusted
OR (95% CI)
Age-and stage-
adjusted OR
(95% CI)
Age o64 years 1.13 (1.10–1.16)
Stage III/IV 1.14 (1.10–1.19) 1.13 (1.08–1.18)
Surgical treatment 0.82 (0.79–0.85) 0.83 (0.80–0.87) 0.85 (0.80–0.91)
Breast conserving
surgery
a
0.89 (0.87–0.92) 0.92 (0.89–0.95) 0.92 (0.89–0.95)
Mastectomy
a 1.09 (1.06–1.12) 1.09 (1.06–1.12) 1.08 (1.05–1.12)
Radiotherapy 0.88 (0.86–0.91) 0.90 (0.88–0.93) 0.91 (0.88–0.94)
BCS and
radiotherapy
b
0.95 (0.90–1.02) 0.96 (0.89–1.02) 0.97 (0.90–1.03)
Chemotherapy 0.96 (0.93–0.99) 1.01 (0.97–1.04) 0.97 (0.93–1.01)
Hormone therapy 1.04 (1.00–1.08) 1.02 (0.99–1.06) 1.04 (1.00–1.08)
Appointment delay
414 days
1.06 (1.02–1.09) 1.06 (1.03–1.10) 1.07 (1.03–1.11)
Treatment delay
414 days
1.02 (1.00–1.05) 1.03 (1.00–1.06) 1.05 (1.02–1.08)
BCS¼breast-conserving surgery; CI¼confidence interval; OR¼odds ratio.
aAnalysis
includes surgery patients only.
bAnalysis includes BCS patients only.
Table 3 Association between socioeconomic status and 5-year survival
from breast cancer for all patients and by type of surgery
Unadjusted HR
(95% CI)
Age-adjusted
HR (95% CI)
Age-and stage
adjusted HR
(95% CI)
All patients 1.14 (1.11–1.16) 1.11 (1.08–1.13) 1.08 (1.05–1.11)
Breast-conserving
surgery group
1.13 (1.07–1.19) 1.14 (1.08–1.20) 1.13 (1.07–1.19)
Mastectomy group 1.05 (1.01–1.09) 1.04 (1.00–1.08) 1.04 (1.00–1.08)
No surgery group 1.04 (1.00–1.08) 1.04 (1.00–1.08) 1.03 (0.98–1.08)
CI¼confidence interval; HR¼hazard ratio.
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results on CT and HT have been inconclusive, with some studies
reporting an association with SEB (Thomson et al, 2001; Taylor
and Cheng, 2003) and others not (Macleod et al, 2000b; Taylor and
Cheng, 2003). In our study, there was no association between
Townsend score and CT, but there was a weak borderline
significant association with HT. The decision to give adjuvant
therapies is complex and depends upon such factors as whether
the patient has undergone surgery and the ER status of the
tumour, making it difficult to draw any firm conclusions from
these results.
Current guidelines state that women should not wait longer
than 14 days between GP referral and a first hospital appointment
or between diagnosis and beginning treatment (National
Institute for Clinical Excellence, 2002). During our study period,
these targets were met in approximately 60% of cases. Women
living in more deprived areas were more likely to wait more
than 14 days for a hospital appointment than those in more
affluent areas, though these results are limited by the fact that
data were missing in 32% of cases. A weaker association between
SEB and treatment delay was also apparent, which could
indicate an influence of SEB on management. Nevertheless,
although long delays by the patient are associated with
decreased survival (Richards et al, 1999), delays by providers
have not previously been linked to poorer outcomes (Sainsbury
et al, 1999).
Living in a more deprived area was associated with lower 5-year
survival. The age-adjusted HR was 1.11 (95% CI 1.08–1.13) per
quartile increase in Townsend score and this reduced to 1.08
(95% CI 1.05–1.11) when additionally adjusted for stage. A
previous study found that adjusting for stage did not substantially
change the estimated HRs for deprivation category (Kaffashian
et al, 2003). One explanation for this is that the adjustment
for stage is insufficient because stage is not a sensitive enough
measure to capture the variation in disease. For example,
stage IV patients could present with early metastatic spread or
may have such advanced disease that no treatment, other than
palliative care, can be given. Stage therefore fails to act as an
adequate proxy for preceding confounders associated with severity
of disease.
Several others studies have concluded that prognostic factors,
such as tumour stage, grade, size, and lymph node status only
partly account for the differences in survival by SEB (Carnon et al,
1994; Macleod et al, 2000a; Brewster et al, 2001). Another factor
associated with SEB is ER status, with patients living in more
deprived areas having higher levels of ER negative tumours
(Twelves et al, 1998; Thomson et al, 2001; Taylor and Cheng,
2003). It has been reported that these tumours appear to have a
worse prognosis, though the difference in ER status was estimated
to explain only about a third of the survival difference by SEB
(Thomson et al, 2001).
As well as prognostic factors, there are many other potential
confounders associated with SEB and with survival. Examples that
are currently unavailable from cancer registry data include level of
education and comorbidity. A higher level of education amongst
those living in the more affluent areas may result in a higher
degree of health awareness, better perception of symptoms and less
delay in seeking medical care (Dalton et al, 2006), which may in
turn lead to improved survival. The presence of co-morbidity
has been associated with reduced survival in breast cancer
(Houterman et al, 2004; Louwman et al, 2005), and patients
from deprived areas may have a higher level of comorbidity
(Macleod et al, 2000b).
It appears that the association between SEB and survival is
stronger in patients undergoing BCS, which cannot be explained
by RT, as there were no RT differences between deprived and
affluent areas. However, the BCS group will contain a higher
proportion of screen-detected tumours, which are likely to be
smaller and have a good prognosis. If the number of screen-
detected cases was higher in the more affluent areas, this may
explain some of the observed survival advantage. Again, the
staging information may not have been sensitive enough to capture
such variation in disease.
There may also be some bias in these results. Potentially, many
risk factors linked to SEB might affect breast cancer outcome.
Statistical adjustment for a confounder or its proxy on the causal
path from exposure to outcome may be subject to the bias known
as the reversal paradox (Stigler, 1999; Kirkwood and Sterne, 2003).
This has recently been shown to be a potentially serious problem
(Tu et al, 2005; Hernandez-Diaz et al, 2006) and may explain some
of the conflicting results concerning breast cancer outcomes
by SEB. For example, a causal relationship may exist between SEB
and stage, perhaps mediated through reduced health awareness
and later presentation amongst those in more deprived areas.
If stage lies on the causal path, then the adjustment for con-
founding becomes mixed with potential bias from the reversal
paradox. In this case, the age-adjusted estimates, though
unbiased, would represent the confounder-unadjusted results,
and the age- plus stage-adjusted estimates would represent the
(biased) confounder-adjusted results. It then becomes impossible
to determine a confounder-adjusted unbiased estimate of the
impact of SEB on survival. Despite these complexities, it is likely
that the true public health effect of SEB on survival is that of
the age-adjusted estimate.
Alternatively, one might make use of stage lying on the causal
path, as it is then a candidate for an intermediate end point
(Freedman et al, 1992), that is, a marker or event that is assessed
before the outcome (survival in this case), and sufficiently
associated with the outcome that it acts as its proxy. From this
perspective, the age- plus stage-adjusted model yields estimates of
the joint effect of SEB and stage on survival. Using Freedman’s
method, it can be estimated how much of the SEB effect on survival
is mediated via the influence of SEB on stage (26% using the age-
adjusted estimate as the denominator). This figure suggests that
stage is not an ideal choice of intermediate end point, though this
might be in part owing to measurement error and missing data
associated with stage. Whether stage is considered as a proxy for
preceding confounders and/or an intermediate end point, it seems
poor in both respects.
This study used an area-based measure of SEB, as an individual
measure is not available from cancer registry data. Owing to the
ecological fallacy (Robinson, 1950), these results cannot be
extended to individual women living in each area. We are
exploring alternative methodologies to address both the ecological
problem and potentially biased adjustment for confounders that lie
on the causal path between SEB and survival.
This study has shown that breast cancer patients living in
more deprived areas were more likely to be diagnosed with
later stage disease than those in more affluent areas and that
there were significant differences in the type of treatment
received. Living in a more deprived area was associated with
decreased survival, perhaps owing to later presentation and
more complex treatment decisions. Part of this survival gap may
be reduced through policies to encourage earlier diagnosis
and appropriate treatment uptake, but the association between
SEB and other factors, such as comorbidity, requires further
investigation.
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